• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[首次急性心肌梗死接受纤维蛋白溶解治疗后的连续缺血事件。对根据临床标准被视为再灌注的GISSI-2患者的分析。GISSI-2研究的参与者。意大利心肌梗死链激酶研究组]

[Successive ischemic events to a first acute myocardial infarct treated with fibrinolysis. An analysis of GISSI-2 patients considered reperfused by a clinical criterion. Participants in the GISSI-2 study. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].

作者信息

Bardelli G, Maggi G, Maggi A, Barlera S

机构信息

Divisione di Cardiologia, Ospedale Fornaroli, Magenta, Milano.

出版信息

G Ital Cardiol. 1995 Apr;25(4):463-72.

PMID:7642053
Abstract

BACKGROUND

The fast normalisation of the ST, after thrombolysis, is early sign related to coronary artery reperfusion and to prognosis of acute myocardial infarction (AMI). The aim of this analysis is the evaluation, in the large patients cohort of the GISSI-2 trial, of the relationship between the ST segment evolution after fibrinolytic therapy of AMI and recurrent ischaemic events [angina-reinfarction-ischaemia to exercise testing (ET)] at 30 and 180 days from randomisation.

METHODS

Patients with first confirmed IMA and ECG before randomisation and 4 hours later, are chosen from GISSI-2 trial. A decrease > or = 50% of the sigma ST elevation is adopted as cutoff for predicting coronary artery patency. Recanalisation is deemed to have occurred in group A patients versus not reperfused group B patients. The studied events are: angina, reinfarction, mortality, at 30 and 180 days from randomisation; ischemia to ET SL of 4-6 week. The results are presented in terms of Mantel-Haenszel odds ratios (OR) and 95% confidence intervals.

RESULTS

Group A patients n. 5307 experienced versus group B patients n. 2718 a higher incidence of--in-hospital angina: 10.3% vs 7.9% OR 1.30 (1.11-1.52)-180 days reinfarction: 2.9% Vs 1.7% OR 1.66 (1.19-2.30)-Ischaemia to ET 25.4% vs 21.4% OR 1.24 (1.08-1.43), and a lower in-hospital mortality: 3.8% vs 8.5% OR 0.39 (0.32-0.48).

CONCLUSIONS

Patients having indirect signs of early reperfusion post thrombolysis for IMA experience a higher in-hospital and 180 days recurrent ischaemia and a lower mortality; this fact can allow early identification of the patients who can receive a benefit from different therapeutical strategies.

摘要

背景

溶栓后ST段快速恢复正常是与冠状动脉再灌注及急性心肌梗死(AMI)预后相关的早期征象。本分析的目的是在GISSI - 2试验的大量患者队列中,评估AMI溶栓治疗后ST段演变与随机分组后30天和180天时复发性缺血事件[心绞痛 - 再梗死 - 运动试验(ET)时的缺血]之间的关系。

方法

从GISSI - 2试验中选取随机分组前及4小时后首次确诊IMA和心电图的患者。采用ST段抬高总和下降≥50%作为预测冠状动脉通畅的截断值。A组患者视为再通,B组患者视为未再灌注。研究的事件包括:随机分组后30天和180天时的心绞痛、再梗死、死亡率;4 - 6周运动试验时的缺血。结果以Mantel - Haenszel优势比(OR)和95%置信区间表示。

结果

A组5307例患者与B组2718例患者相比,住院期间心绞痛发生率更高:10.3%对7.9%,OR 1.30(1.11 - 1.52);180天时再梗死发生率:2.9%对1.7%,OR 1.66(1.19 - 2.30);运动试验时缺血发生率:25.4%对21.4%,OR 1.24(1.08 - 1.43),且住院死亡率更低:3.8%对8.5%,OR 0.39(0.32 - 0.48)。

结论

溶栓后有IMA早期再灌注间接征象的患者住院期间及180天时复发性缺血发生率更高,死亡率更低;这一事实有助于早期识别可从不同治疗策略中获益的患者。

相似文献

1
[Successive ischemic events to a first acute myocardial infarct treated with fibrinolysis. An analysis of GISSI-2 patients considered reperfused by a clinical criterion. Participants in the GISSI-2 study. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].[首次急性心肌梗死接受纤维蛋白溶解治疗后的连续缺血事件。对根据临床标准被视为再灌注的GISSI-2患者的分析。GISSI-2研究的参与者。意大利心肌梗死链激酶研究组]
G Ital Cardiol. 1995 Apr;25(4):463-72.
2
[The predictive value for major arrhythmic events of ventricular arrhythmias, particularly nonsustained ventricular tachycardias, in the subacute phase of a fibrinolyzed infarct. An analysis of GISSI-2 data. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].[在溶栓治疗心肌梗死亚急性期,室性心律失常尤其是非持续性室性心动过速对主要心律失常事件的预测价值。GISSI-2数据的分析。意大利心肌梗死链激酶研究组]
G Ital Cardiol. 1995 Jan;25(1):77-87.
3
[The evolution of hospital mortality due to acute myocardial infarct in the first 2 GISSI studies. Participants in the GISSI 1 and GISSI 2 studies. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].[前两项GISSI研究中急性心肌梗死所致医院死亡率的演变。GISSI 1和GISSI 2研究的参与者。意大利心肌梗死链激酶研究组]
G Ital Cardiol. 1994 Dec;24(12):1597-604.
4
A simple electrocardiographic predictor of the outcome of patients with acute myocardial infarction treated with a thrombolytic agent. A Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2)-Derived Analysis.一种用于预测接受溶栓剂治疗的急性心肌梗死患者预后的简单心电图指标。源自意大利心肌梗死存活研究组(GISSI - 2)的分析。
J Am Coll Cardiol. 1994 Sep;24(3):600-7. doi: 10.1016/0735-1097(94)90003-5.
5
Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2).接受溶栓治疗的首次心肌梗死患者中与年龄相关的死亡率增加。意大利心肌梗死存活研究组(GISSI - 2)的研究人员。
N Engl J Med. 1993 Nov 11;329(20):1442-8. doi: 10.1056/NEJM199311113292002.
6
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.急性心肌梗死后接受溶栓和抗栓治疗患者的卒中风险。意大利心肌梗死存活研究组II(GISSI-2)及国际研究组。
N Engl J Med. 1992 Jul 2;327(1):1-6. doi: 10.1056/NEJM199207023270101.
7
[The safety and efficacy of systemic salvage thrombolysis in acute myocardial infarct].急性心肌梗死全身挽救性溶栓治疗的安全性与有效性
Ital Heart J Suppl. 2000 Jan;1(1):81-7.
8
[Atenolol i.v. in the acute phase of AMI: the indications, contraindications and interactions with thrombolytic drugs in the GISSI-2 study. The GISSI-2 Researchers. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].急性心肌梗死急性期静脉注射阿替洛尔:GISSI - 2研究中其适应证、禁忌证及与溶栓药物的相互作用。GISSI - 2研究人员。意大利心肌梗死链激酶研究组
G Ital Cardiol. 1995 Mar;25(3):353-64.
9
Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. GISSI-2 and International Study Group. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto.20891例急性心肌梗死患者被随机分为接受阿替普酶和链激酶治疗(加或不加肝素),对其进行六个月生存率的研究。GISSI - 2和国际研究小组。意大利心肌梗死生存研究组。
Eur Heart J. 1992 Dec;13(12):1692-7.
10
[Prognostic stratification at discharge after acute myocardial infarct: the significance of the female sex. Participants in the GISSI-2 study. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico].急性心肌梗死后出院时的预后分层:女性的意义。GISSI-2研究的参与者。意大利心肌梗死链激酶研究组
G Ital Cardiol. 1994 Dec;24(12):1585-95.